Drs. Eric Rowinsky and James Tonra: A New Phase 1/​1B Study of ST-01156, a Small Molecule RBM39 Protein Degrader

Drs. Eric Rowinsky and James Tonra of Seed Therapeutics present on recently opened clinical trial (NCT07197554) for solid tumor, with specific focus on Ewing sarcoma. ST-01165 is a orally administered, protein degrader (molecular glue), targeting RMB39 - a key regulator of RNA splicing and transcription required for tumor cell proliferation.